HIVインテグラーゼ阻害活性を有するヘテロ環化合物
    1.
    发明申请
    HIVインテグラーゼ阻害活性を有するヘテロ環化合物 审中-公开
    具有HIV整合抑制活性的杂环化合物

    公开(公告)号:WO2004024693A1

    公开(公告)日:2004-03-25

    申请号:PCT/JP2003/010212

    申请日:2003-08-11

    Abstract: A compound having antiviral activity, specifically a heterocyclic compound having HIV integrase inhibitory activity; and a medicine containing the compound, especially an anti-HIV drug. The compound is a compound represented by the formula (I): (I) [wherein B is -C(R )= or -N=; R ' is hydrogen, etc.; one of R and R is a group represented by the formula -Z -Z -Z -R (wherein Z and Z each independently is a single bond, optionally substituted alkylene, etc.; Z is a single bond, optionally substituted alkylene, etc.; and R is optionally substituted aryl, optionally substituted heteroaryl, etc.) and the other is hydrogen; and -A - is -C(-Y)=C(-R )-C(-R )=C(-R )- (wherein Y is -OH, etc.; R is -COR (R is hydroxy, etc.), etc.; and one of R and R is carboxy, etc. and the other is hydrogen, etc.), etc.], a prodrug of the compound, a pharmaceutically acceptable salt of either, or a solvate of any of these.

    Abstract translation: 具有抗病毒活性的化合物,特别是具有HIV整合酶抑制活性的杂环化合物; 以及含有该化合物,特别是抗HIV药物的药物。 化合物是由式(I)表示的化合物:(I)[其中B 1是-C(R 2)=或-N =; R 1是氢等; R 1和R 2中的一个是由式-Z 1 -Z 2 -Z 3 -R 5表示的基团(其中Z 1和Z 3各自独立地 独立地是单键,任选取代的亚烷基等; Z 2是单键,任选取代的亚烷基等;且R 5是任选取代的芳基,任选取代的杂芳基等),另一个是 氢; 并且-A 1 - 是-C(-Y)= C(-R A)-C(-R 3)= C(-R 4) - (其中Y是-OH等) R 7是-COR 7(R 7是羟基等)等; R 3和R 4之一是羧基等,另一个是氢, 等等),化合物的前体药物,其药学上可接受的盐或其中任何一种的溶剂合物。

    HIVインテグラーゼ阻害活性を有するナフチリジン誘導体
    2.
    发明申请
    HIVインテグラーゼ阻害活性を有するナフチリジン誘導体 审中-公开
    具有HIV整合酶抑制活性的萘啶衍生物

    公开(公告)号:WO2005075475A1

    公开(公告)日:2005-08-18

    申请号:PCT/JP2005/001454

    申请日:2005-02-02

    CPC classification number: C07D471/04

    Abstract: [PROBLEMS] To provide a novel compound having antiviral activity, especially HIV integrase inhibitory activity; and a medicine, in particular, an anti-HIV drug, which contains the compound. [MEANS FOR SOLVING PROBLEMS] The compound is one represented by the formula (I) [wherein R is optionally substituted aralkyl; R and R each independently is hydrogen, optionally substituted alkyl, etc. (provided that the substituent(s) with which the alkyl is "optionally substituted" are noncyclic groups); and R is hydrogen, optionally substituted carboxy, etc.] or a salt thereof.

    Abstract translation: [问题]提供具有抗病毒活性的新化合物,特别是HIV整合酶抑制活性; 以及含有该化合物的药物,特别是抗HIV药物。 解决问题的方法化合物是由式(I)表示的化合物[其中R 1是任选取代的芳烷基; R 2和R 3各自独立地是氢,任选取代的烷基等(条件是烷基被“任选取代”的取代基是非环基团); 和R 4是氢,任选取代的羧基等]或其盐。

    HIVインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
    3.
    发明申请
    HIVインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体 审中-公开
    具有艾滋病毒整合的抑制活性的多环碳酰胺基衍生物

    公开(公告)号:WO2007049675A1

    公开(公告)日:2007-05-03

    申请号:PCT/JP2006/321335

    申请日:2006-10-26

    Abstract: Disclosed is a novel compound having an anti-viral activity, particularly an inhibitory activity on HIV integrase. Also disclosed is a pharmaceutical, particularly an anti-HIV agent, comprising the compound. The compound is represented by the formula (I): (I) wherein R 1 represents a hydrogen or a lower alkyl; X represents a lower alkylene or the like; R 2 represents an aryl which may be substituted; R 3 represents a hydrogen, a halogen, a hydroxy, or the like; R 4 represents a hydrogen, a lower alkyl group which may be substituted or the like; the broken line represents the presence or absence of a bond; one of B 1 and B 2 represents CR 20 R 21 and the other represents NR 22 wherein no broken line is present, or B 1 and B 2 independently represent C, CR 23 or N wherein the B 1 moiety and the B 2 moiety may together form a heterocyclic ring which may be substituted; and R 20 , R 21 , R 22 and R 23 independently represent a hydrogen, a lower alkyl which may be substituted, a cycloalkyl which may be substituted, a cycloalkyl(lower)alkyl which may be substituted or the like.

    Abstract translation: 公开了具有抗病毒活性的新型化合物,特别是对HIV整合酶的抑制活性。 还公开了包含该化合物的药物,特别是抗HIV剂。 该化合物由式(I)表示:(I)其中R 1表示氢或低级烷基; X表示低级亚烷基等; R 2表示可被取代的芳基; R 3表示氢,卤素,羟基等; R 4表示氢,可以被取代的低级烷基等; 虚线代表债券的存在与否; B 1和B 2之一表示CR 20 R 21,另一个表示NR 22, / SUP>其中不存在虚线,或B 1和B 2独立地表示C,CR 23或N,其中B 1个部分和B 2 O 2部分可以一起形成可被取代的杂环; 和R 20,R 21,R 22和R 23独立地代表氢,可以是低级烷基 可以被取代的环烷基,可以被取代的环烷基(低级)烷基等。

Patent Agency Ranking